Prof. Montalban discusses long-term treatment for multiple sclerosis with older and more recent disease-modifying therapies, and switching between the two.1/3 Next Interview
Prof. Havrdová discusses the concept of initiating therapy with highly effective therapies for multiple sclerosis and discusses the available data.2/3 Next Interview
Dr Ben-Zacharia reviews the crucial role of treatment adherence in multiple sclerosis and the importance of shared decision-making in achieving optimal clinical outcomes.3/3 Take CE/CME Test
Learning Objectives & Overview
In this activity, multiple sclerosis experts present their thoughts on the latest data with highly effective disease-modifying therapies and what they mean for treatment decisions.
This activity has been jointly provided by Oakstone and touchIME NEUROLOGY. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians. read more
This activity has been designed to meet the educational needs of neurologists, multiple sclerosis specialists and neurology nurses involved in the management of multiple sclerosis.
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest have been mitigated. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relationships with ineligible entities.
Prof. Xavier Montalban discloses: Speaker honoraria/compensation for advisory board or scientific meeting participation from Actelion, Alexion, Bayer, Biogen, Celgene, EMD Serono, Exemed, Genzyme, Immunic, Medday, Merck, Multiple Sclerosis International Federation, Mylan, Nervgen, Novartis, Roche, Sanofi Genzyme, Teva Pharmaceuticals, TG Therapeutics and US National MS Society.
Prof. Eva Kubala Havrdová discloses: Speaker honoraria/compensation for advisory board participation from Actelion, Biogen, Celgene, Merck, Novartis, Roche and Sanofi Genzyme.
Dr Aliza B Ben-Zacharia discloses: Consultancy fees from Biogen, Genentech and Greenwich Biosciences.
Walter Murray Yarbrough, MD, FACP, has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Christina Mackins-Crabtree has no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and touchIME. Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.
This content is intended only for healthcare professionals.
Date of original release: 8 June 2021. Date credits expire: 8 June 2022.
After watching this activity, participants should be better able to:
- Describe the latest data informing the use of disease-modifying therapies in the treatment of multiple sclerosis
- Evaluate the potential benefit of early treatment with highly effective disease-modifying therapies for patients with multiple sclerosis
- Explain how patient-centric decision making can improve outcomes